A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

January 28, 2016

Primary Completion Date

November 23, 2022

Study Completion Date

November 23, 2022

Conditions
Hematologic MalignanciesSolid Tumor
Interventions
DRUG

PF-0791800 (TTI-621)

Monotherapy

DRUG

PF-07901800 (TTI-621) plus Rituximab

Combination therapy

DRUG

PF-07901800 (TTI-621) plus Nivolumab

Combination therapy

Trial Locations (51)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

NYU Investigational Pharmacy, New York

NYU Langone Health (Tisch Hospital), New York

10017

Memorial Sloan Kettering Cancer Center-Clinical Trails Office, New York

10019

Columbia Univeristy, New York

10021

Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care, New York

10022

Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion, New York

10032

Columbia University Medical Center., New York

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Cancer Center Westchester, Harrison

15213

University of Pittsburgh Medical Center Presbyterian Shadyside, Pittsburgh

15237

University of Pittsburgh Medical Center, Pittsburgh

32224

Mayo Clinic Jacksonville, Jacksonville

Mayo Clinic, Jacksonville

33612

Moffitt Cancer Center Richard M Schulze Family Foundation Outpatient Center at McKinley Campus, Tampa

Moffitt Cancer Center, Tampa

37203

Centennial Medical Center, Nashville

Sarah Cannon Research Institute (Pharmacy), Nashville

Tennessee Oncology PLLC, Nashville

Tennessee Oncology, PLLC, Nashville

Tennessee Oncology, Nashville

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

Cleveland Clinic, Cleveland

46140

Covance Biorepository, Greenfield

55905

Mayo Clinic, Rochester

77030

The University of Texas MD Anderson Cancer Center, Houston

University of Texas MD Anderson Cancer Center, Cancer Prevention Center, Houston

University of Texas MD Anderson Cancer Center, Melanoma and Skin Clinic, Houston

University of Texas MD Anderson Cancer Center, Houston

78759

Myriad RMB Inc, Austin

80218

Colorado Blood Cancer Institute, Denver

Presbyterian/St.Luke's Medical Center, Denver

91010

City of Hope National Medical Center, Duarte

City of Hope, Duarte

94304

Freidenrich Center for Translational Research (CTRU), Palo Alto

Stanford Cancer Institute, Palo Alto

97239

Oregon Health & Science University-Research Pharmacy Services, Portland

Oregon Health & Science University, Portland

Oregon Health and Sciences University, Portland

98109

Seattle Cancer Care Alliance, Seattle

University of Washington - Seattle Cancer Care Alliance, Seattle

98195

University of Washington Medical Center, Seattle

07601

Hackensack Meridian Health John Theurer Cancer Center, Hackensack

Hackensack UMC, Hackensack

The John Theurer Cancer Center at Hackensack UMC, Hackensack

07748

Memorial Sloan Kettering Cancer Center- Monmouth, Middletown

V5Z1H7

Fairmont Medical Building, Suite 810, Vancouver

V5Z 1H6

British Columbia Cancer Agency, Vancouver

M5G 2M9

Princess Margaret Cancer Center, Toronto

University Health Network - Princess Margaret Cancer Centre, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02663518 - A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors | Biotech Hunter | Biotech Hunter